Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP NEWS IN BRIEF -7-
June 11, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 11, 2001
- Sysmex: Sales Down in US, Japan, but Up in Europe, Asia
June 11, 2001
- 2% Price Adjustment Range Needs Urgent Review: FJPWA
June 11, 2001
- Olympus: Good Sales of Medical Endoscopes Overseas Drive Sales, Profits
June 11, 2001
- Nippon BD Ties Up with TAUNS Regarding Infectious Disease Diagnosis Kits
June 11, 2001
- Richfield to Embark on MR Dispatching Business
June 11, 2001
- Olympus: New Endoscope Position Detective Unit
June 11, 2001
- Matsumotokiyoshi: Sales Up 1% but Operating Profits Down 0.9%
June 11, 2001
- Tokyo Women's Medical Univ. Introduces "MR-kun"
June 11, 2001
- Genzyme Aims at Leading Biosurgery Market
June 11, 2001
- New Quasi-drug Sales Up 8.5%, to \155.3 Bil.
June 11, 2001
- JKMA Proposes New Development for Kampo Medicines
June 11, 2001
- Boston Scientific Japan: Exxcel Soft, Artificial Blood Vessel
June 11, 2001
- WORLD NEWS IN BRIEF
June 11, 2001
- Mevalotin Inhibits Coronary Events, Cerebral Infarctions
June 11, 2001
- Sankyo to Cut Over \90 Bil. in Costs to Achieve Sales of \1,000 Bil. in FY2010: President Takato
June 11, 2001
- JPPA Kicks Off Division of Women
June 11, 2001
- 30 Major Domestic Drug Companies: Sales Up 2.1%, Profits Up 3.0%
June 11, 2001
- EAD Director Calls For Fair Trade Practices for Ethical Drugs
June 11, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…